Cancer Patients' Gray Hair Turned Dark in Trials for New Immune Drugs - NBC New York
National & International News
The day’s top national and international news

Cancer Patients' Gray Hair Turned Dark in Trials for New Immune Drugs

A team of Spanish researchers found 14 cases where patients being treated with new immunotherapy drugs had hair turn brown or black

    processing...

    NEWSLETTERS

    Cancer Patients' Gray Hair Turned Dark in Trials for New Immune Drugs
    JAMA via AP Photo
    This undated combination of photos provided by the Journal of the American Medical Association in July 2017 shows a cancer patient with gray hair that unexpectedly turned dark while taking new immunotherapy drugs. Fourteen such cases were among 52 lung cancer patients being followed to see whether they developed bad side effects from the drugs - Keytruda, Opdivo and Tecentriq.

    Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

    Chemotherapy is notorious for making hair fall out, but the 14 patients involved were all being treated with new immunotherapy drugs that work differently and have different side effects. A Spanish study suggests that may include restoring hair pigment, at least in patients with lung cancer.

    With the first patient, "we thought it could be an isolated case," said Dr. Noelia Rivera, a dermatologist at Autonomous University of Barcelona.

    But she said the research team found the same thing when they asked other patients for photos from before treatment.

    Olympians Share Their Most Embarrassing School Memories

    [NATL] Olympians Share Their Most Embarrassing School Memories

    From bad school pictures to awkward first day wardrobes, Team USA members can now look back on some of their most embarrassing school moments and laugh.

    (Published Friday, Aug. 18, 2017)

    The 14 cases were among 52 lung cancer patients being followed to see whether they developed bad side effects from the drugs — Keytruda, Opdivo and Tecentriq.

    While most patients did not have a color change, the 14 cases suggest it's not an isolated finding. In 13 patients, hair turned darkish brown or black. In one patient, it turned black in patches.

    In another odd twist, the same drugs have been linked previously with hair losing color in patients with another cancer, melanoma.

    All but one of the 14 patients in the Spanish study had at least stable disease and responded better to treatment than other patients, suggesting that hair darkening might be an indication that the drugs are working, the researchers said.

    Rivera said they are continuing the study to search for an explanation and to see if the cases are just a fluke.

    "It's a fascinating report — one of those things that comes out of the blue," said Dr. June Robinson, a Northwestern University research professor in dermatology. Robinson is also editor of the medical journal JAMA Dermatology, which published the study online this month.

    2 Dead, 6 Injured in Knife Attack in Turku, Finland

    [NATL] 2 Dead, 6 Injured in Knife Attack in Turku, Finland

    Finland police said a man stabbed several people in Turku, Finland. Two people are confirmed dead and six others are injured. Police officers shot one suspect in the leg and took him into custody. Warnings were posted throughout the city for people to stay away from the downtown area.

    (Published Friday, Aug. 18, 2017)

    She said the results deserve a deeper look but cautioned that it's way too soon to suggest that they might lead to new treatments for gray hair.

    Rivera noted that the study drugs have serious side effects that make them unsafe for healthy people. But if it's confirmed that they do change hair color, a different drug could be developed to treat gray hair, she said.

    The pharmaceutical industry has previously capitalized on unexpected drug side effects; examples include the male pattern baldness drug Propecia, the eyelash growing drug Latisse, and Botox anti-wrinkle injections. Active ingredients in these drugs were initially approved to treat enlarged prostates, eye pressure problems, and eye muscle spasms.